News for Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top pharmaceutical stocks.

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its sales and profit estimates.

Baker Hughes (BKR) is set to acquire Chart Industries (GTLS) for a substantial $13.6 billion in an all-cash deal, valued at $210 per share. This strategic

An increasing number of analysts are pointing out that the AI revolution that started with the launch of ChatGPT is here to stay, and we are still in the early innings of a broader AI infrastructure build...

Eli Lilly and Company (NYSE:LLY) is among the 12 Best Ethical Companies to Invest in 2025. Eli Lilly and Company (NYSE:LLY) is experiencing a strong analyst sentiment amid its expanding role in cutting-edge treatments. On July 18, Leerink Partners maintained its ‘Buy’ rating on the company, citing growth potential through the GLP-1 receptor agonist (GLP-1RA) […]

Eli Lilly and Company (LLY) has finalized its acquisition of Verve Therapeutics, a clinical-stage firm located in Boston. Verve Therapeutics focuses on the deve

Eli Lilly (LLY) completes acquisition of Verve Therapeutics (VERV) to advance genetic medicines for cardiovascular disease. The acquisition aims to deve

PR NewswireINDIANAPOLIS, July 25, 2025 INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful complet

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on LLY.

PR NewswireINDIANAPOLIS, July 24, 2025 INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025

PR NewswireINDIANAPOLIS, July 24, 2025 INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ:

Eli Lilly (LLY) concludes tender offer for Verve Therapeutics (VERV) shares. Approximately 55.7% of Verve's shares were tendered by the expiration time.

Tariffs are wielded by Trump to leverage critical concessions and protect US interests. The pharma industry is one in which this leverage has had considerable success.

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of […]

Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might […]

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

Baron Health Care Fund declined for the quarter but outperformed its benchmark, the Russell 3000 Health Care Index. Read more here.